ImCheck Appoints Stephan Braun as Chief Medical Officer
July 09 2024 - 5:00AM
ImCheck Appoints Stephan Braun as Chief
Medical
Officer
Marseille, France, July 09,
2024 – ImCheck Therapeutics announced today the
appointment of Stephan Braun, M.D., Ph.D., as Chief Medical
Officer. Dr. Braun brings over 30 years of drug development
experience gained from an extensive career in both the
pharmaceutical industry and in academic research. He joins ImCheck
to support the ongoing clinical development of lead candidate
ICT01, a γ9δ2 T cell-activating monoclonal antibody targeting
BTN3A, as it moves toward later-stage trials in multiple cancer
indications, as well as a growing pipeline of immunotherapeutic
antibodies that harness the innate and adaptive immune
responses.
“As ICT01 continues to demonstrate its
therapeutic potential, evidenced by the data from the EVICTION
trial, it is the right time to add a clinical expert with Stephan’s
pedigree to our team. His extensive expertise in oncology-focused
drug development will be instrumental as we accelerate ICT01’s
progress in the clinic and further expand our pipeline beyond
cancer,” said Pierre
d’Epenoux, Chief Executive Officer of ImCheck
Therapeutics.
Dr. Stephan Braun,
Chief Medical Officer of ImCheck
Therapeutics,
added, “With its pioneering
research in immunomodulation and strong clinical development plan,
ImCheck represents an exciting opportunity to develop a pipeline of
immunotherapeutic antibodies targeting butyrophilins in cancer,
autoimmune and infectious disease indications. I look forward to
working with the outstanding ImCheck team to advance these programs
and contribute to the company's clinical success.”
Before joining ImCheck, Dr. Stephan Braun served
as Group Chief Medical Officer at CureTeq AG. He previously held
executive and leadership roles at Basilea, Ipsen, Parexel and
Symphogen. He was also the Medical Director of Clinical Development
and a Senior Medical Scientist at Amgen, where he was involved in
the development, approval and medical affairs activities for
several drugs including Aranesp, Xgeva, and Vectibix. During his
academic tenure, Dr. Braun was a professor at the Department of
Obstetrics and Gynecology at the medical universities in Munich and
Innsbruck from 1994 until 2008 building and leading the Breast
Cancer Center and Gynecologic Oncology Center teams. He has
authored 35 peer-reviewed publications and several book chapters in
translational research and oncology and served on the editorial
boards of several scientific journals. In addition, he is an active
member of the American Society of Clinical Oncology (ASCO),
American Association for Cancer Research (AACR), American Society
of Hematology (ASH), and European Society for Medical Oncology
(ESMO).
***
About IMCHECK THERAPEUTICS
ImCheck Therapeutics is designing and developing
a new generation of immunotherapeutic antibodies targeting
butyrophilins, a novel super-family of immunomodulators.
As demonstrated by its lead clinical-stage
program ICT01, which has a mechanism of action to simultaneously
modulate innate and adaptive immunity, ImCheck's
“first-in-class” activating antibodies may be able to produce
superior clinical results as compared to the first-generation of
immune checkpoint inhibitors and, when used in combination, to
overcome resistance to this group of agents. In addition, ImCheck’s
antagonist antibodies are being evaluated as potential treatments
for a range of autoimmune and infectious diseases.
ImCheck benefits from support from Prof. Daniel
Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille
University), a worldwide leader in γ9δ2 T cells and butyrophilins
research, as well as from the experience of an expert management
team and from the commitment of leading US and European
investors.
For further information:
https://www.imchecktherapeutics.com/
Press contacts:
US and EU Trophic
CommunicationsGretchen Schweitzer +49 (0) 172 861
8540imcheck@trophic.eu
FranceATCG
PARTNERSCéline Voisin+33 (0)9 81 87 46 72 / +33 (0)6 62 12
53 39imcheck@atcg-partners.com